Search
Ixazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016. … [A7948] More than 99% of the drug compound is the R-enantiomer.[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexBrivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. … Briviact received FDA approval on February 19, 2016 [L760].
Thiocolchicoside
go.drugbank.com/drugs/DB11582InvestigationalThiocolchicoside is a semi-synthetic derivative of the colchicine, a natural anti-inflammatory glycoside which originates from the flower seeds of _Superba gloriosa_. … It is a muscle relaxant with anti-inflammatory and analgesic effects. It has potent convulsant activity and should not be administered to individuals prone to seizures.[L1663]
Mixtures: MERDEX DUO %5 + %0.25 TOPIKAL JEL, 30 G, MAJEZIK DUO %5 + %0.25 TOPIKAL JEL, 50 GSevelamer
go.drugbank.com/drugs/DB00658ApprovedInvestigationalSevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Categories: Compounds used in a research, industrial, or household setting, Drugs for Treatment of Hyperkalemia and HyperphosphatemiaAvacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigationalAnti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified … [A240254, A240259, A240264, A240269] Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV.
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.
Peginterferon alfa-2b
go.drugbank.com/drugs/DB00022ApprovedInvestigationalPeginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Peginterferon alfa-2b is available as a variable dose injectable product (tradename Pegintron) used for the treatment of chronic Hepatitis C.
Categories: Compounds used in a research, industrial, or household settingLopinavir
go.drugbank.com/drugs/DB01601ApprovedInvestigationalLopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. … Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity.
Categories: Metabolic Side Effects of Drugs and Substances, Antivirals used in combination for the treatment of HIV infectionsEnalaprilat
go.drugbank.com/drugs/DB09477ApprovedInvestigationalEnalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible. … As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume
Categories: Agents Acting on the Renin-Angiotensin SystemBictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalBictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. … It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677]
Categories: Antivirals used in combination for the treatment of HIV infections